Table 3.

Hematologic and non-hematologic toxicity.^*

Hematologic
	Median time to nadir (range)		Median nadir value (range)		Patients with grade 3 or 4 nadir		Patients with grade 4 nadir
Absolute neutrophil count (cells/mm3)	7 weeks (5–9)		1,000 (210–2,100)		29%		7%
Platelets (cells/mm3)	5 weeks (3–8)		51,000 (22,000– 129,000)		46%		0%
Hemoglobin (gm/dL)	7 weeks (4–13)		11.8 (7.4–13.5)		18%		0%
Non-hematologic adverse event
System		Grade 1	Grade 2	Grade 3	Grade 4	No.	Total^ %
Skin
Green discoloration		11	12	0	0	23	79
Pruritis		5	0	0	0	5	17
Body as whole
Fatigue		18	4	0	0	22	76
Hypoabluminema		9	6	0	0	15	52
Infection		2	7	1	0	9	31
Chills/rigors (during rituximab)		5	2	0	0	7	24
Insomnia		6	1	0	0	7	24
Headache		3	3	0	0	6	21
Edema		1	4	0	0	5	17
Pain (myalgia)		2	2	0	0	4	14
Gastrointestinal
Constipation		11	3	0	0	14	48
Nausea		11	1	0	0	12	41
Diarrhea		4	0	0	0	4	14
Vomiting		4	0	0	0	4	14
Hepatic
Transaminases		11	1	0	0	12	41
Alkaline phosphatase		10	0	0	0	10	34
GGT elevation		8	1	0	0	9	31
Bilirubin		7	0	0	0	7	24
Cardiovascular
Hypertension		8	0	0	0	8	28
Tachycardia		6	0	0	0	6	21
Electrolytes
Hyponatremia		7	0	0	0	7	24
Hypophosphatemia		3	3	0	0	6	21
Hypokalemia		4	0	1	0	6	21
Hypocalcemia		5	0	0	0	5	17
Bicarbonate		4	0	0	0	4	14
Hypomagnesemia		4	0	0	0	4	14
Renal
Creatinine		4	0	0	0	4	14

^*The incidence included all grade 3 or 4 adverse events and those grade 1 and 2 that occurred in > 10%10% of patients relationship during the treatment period which were classified as probably or possibly related to study drug or relationship unknown.

^{^}Percent of total patients who received MGd/⁹⁰Y ibritumomab tiuxetan (n=29).